In this post hoc secondary analysis of the TODAY randomized clinical trial, we found novel associations of plasma GH mediator levels with glycemic failure, measures of glycemia, insulin sensitivity, and beta cell function in youths with T2D. The gene discussed is GH1; the disease is type 2 diabetes mellitus.